These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23867602)

  • 1. Lead identification of novel and selective TYK2 inhibitors.
    Liang J; Tsui V; Van Abbema A; Bao L; Barrett K; Beresini M; Berezhkovskiy L; Blair WS; Chang C; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liimatta M; Mantik P; Menghrajani K; Murray J; Sambrone A; Xiao Y; Shia S; Shin Y; Smith J; Sohn S; Stanley M; Ultsch M; Zhang B; Wu LC; Magnuson S
    Eur J Med Chem; 2013 Sep; 67():175-87. PubMed ID: 23867602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.
    Liang J; Van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair WS; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Goodacre S; Ghilardi N; MacLeod C; Johnson A; Bir Kohli P; Lai Y; Lin Z; Mantik P; Menghrajani K; Nguyen H; Peng I; Sambrone A; Shia S; Smith J; Sohn S; Tsui V; Ultsch M; Williams K; Wu LC; Yang W; Zhang B; Magnuson S
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4370-4376. PubMed ID: 28830649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
    Norman P
    Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells.
    Shiokawa Z; Hashimoto K; Saito B; Oguro Y; Sumi H; Yabuki M; Yoshimatsu M; Kosugi Y; Debori Y; Morishita N; Dougan DR; Snell GP; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2013 Dec; 21(24):7938-54. PubMed ID: 24169315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
    Fensome A; Ambler CM; Arnold E; Banker ME; Clark JD; Dowty ME; Efremov IV; Flick A; Gerstenberger BS; Gifford RS; Gopalsamy A; Hegen M; Jussif J; Limburg DC; Lin TH; Pierce BS; Sharma R; Trujillo JI; Vajdos FF; Vincent F; Wan ZK; Xing L; Yang X; Yang X
    Bioorg Med Chem; 2020 May; 28(10):115481. PubMed ID: 32253095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.
    Maingot L; Elbakali J; Dumont J; Bosc D; Cousaert N; Urban A; Deglane G; Villoutreix B; Nagase H; Sperandio O; Leroux F; Deprez B; Deprez-Poulain R
    Eur J Med Chem; 2013 Nov; 69():244-61. PubMed ID: 24044937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors.
    Sasaki Y; Tokuhara H; Ohba Y; Okabe A; Nakayama M; Nakagawa H; Skene R; Hoffman I; Zou H; Yoshida M
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126963. PubMed ID: 31980341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.
    Jang WD; Kim JT; Son HY; Park SY; Cho YS; Koo TS; Lee H; Kang NS
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3947-52. PubMed ID: 26231159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
    Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
    J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.
    Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S
    J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum.
    Norman P
    Expert Opin Ther Pat; 2014 Mar; 24(3):361-8. PubMed ID: 24386992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.
    Yogo T; Nagamiya H; Seto M; Sasaki S; Shih-Chung H; Ohba Y; Tokunaga N; Lee GN; Rhim CY; Yoon CH; Cho SY; Skene R; Yamamoto S; Satou Y; Kuno M; Miyazaki T; Nakagawa H; Okabe A; Marui S; Aso K; Yoshida M
    J Med Chem; 2016 Jan; 59(2):733-49. PubMed ID: 26701356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.
    Carotenuto A; Cipolletta E; Gomez-Monterrey I; Sala M; Vernieri E; Limatola A; Bertamino A; Musella S; Sorriento D; Grieco P; Trimarco B; Novellino E; Iaccarino G; Campiglia P
    Eur J Med Chem; 2013 Nov; 69():384-92. PubMed ID: 24077529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extraction, chemical characterization and biological activity determination of broccoli health promoting compounds.
    Ares AM; Nozal MJ; Bernal J
    J Chromatogr A; 2013 Oct; 1313():78-95. PubMed ID: 23899380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of
    Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
    Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
    Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
    Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
    J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.